Treatment of Neurotic Depression with a New Antidepressant

Goldberg, Harold L.; Rickels, Karl; Finnerty, Richard J.

doi:10.1097/00004714-198111001-00007

Cited by 22 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one of two large outpatient collaborative studies [7], clinical symptoms did not pre dict differential responsiveness to either am itriptyline or trazodone. In the other large outpatient study [6], trazodone and amitrip tyline were equally effective in decreasing psychomotor retardation. In two studies [3,10], trazodone was more effective than the tricyclic agent (amitriptyline or imipramine) in decreasing symptoms of anxiety early in treatment (but not at the conclusion of the study) while being at least equally effective in decreasing core depressive symptoms.…”

Section: Efficacymentioning

confidence: 88%

“…Six of these studies included substantial percentages of endogenously de pressed patients (39-100%) [3-5, 7, 9, 10], and four included inpatients [3,5,9,10]. Five of the seven studies [3,6,7,9,10] involved a 6-week trial; the remaining two [4,5] used a 4-week protocol. Amitriptyline was the comparative agent in four of the seven trials [6,7,9,10]; imipramine was the comparative agent in the remaining three [3][4][5].…”

Section: Methodsmentioning

confidence: 99%

“…Five of the seven studies [3,6,7,9,10] involved a 6-week trial; the remaining two [4,5] used a 4-week protocol. Amitriptyline was the comparative agent in four of the seven trials [6,7,9,10]; imipramine was the comparative agent in the remaining three [3][4][5]. The four American studies included placebo control groups [4][5][6][7], whereas the three European studies did not [3,9,10].…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Trazodone: A 5-Year Review of Antidepressant Efficacy

Schatzberg

1987

Psychopathology

View full text Add to dashboard Cite

Results from double-blind studies reported since 1981 were reviewed to evaluate trazodone’s relative antidepressant efficacy and its safety profile. Trazodone’s therapeutic efficacy compared favorably with that of the tricyclic antidepressant (TCA) agents in both endogenous and nonendogenous patients. Data also suggested that trazodone had a more pronounced, earlier anxiolytic action than the TCA agents. Trazodone may be more effective at lower than maximal doses; some studies that used high dosages-starting at 200 mg/day and rapidly titrated doses to as high as 600 mg/day–reported poorer therapeutic responses than did those that employed more conservative dosages. Trazodone therapy generally produced less pronounced anticholinergic effects than did the comparison TCA agent and it is often as sedating as amitriptyline but more sedating than imipramine. Untoward side effects may be reduced by taking trazodone after meals, and by using bedtime dosing. Issues of possible cardiotoxicity and priapism are reviewed briefly. Overall, studies in the past 5 years point to trazodone as being an effective antidepressant agent with a relatively favorable safety profile.

show abstract

Section: Efficacymentioning

confidence: 88%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Trazodone: A 5-Year Review of Antidepressant Efficacy

Schatzberg

1987

Psychopathology

View full text Add to dashboard Cite

show abstract

“…Other studies have demonstrated that tra zodone may be useful in geriatric patients with organic brain syndromes [37], has a rel atively rapid onset of action [30,31,38] and diminishes the anxiety and agitation that fre quently accompany depression [39][40][41].…”

Section: Discussionmentioning

confidence: 99%

Comparative Side Effect Profiles of Trazodone and Imipramine: Special Reference to the Geriatric Population

Gershon¹

1984

Psychopathology

View full text Add to dashboard Cite

Side effects are a concomitant of almost all therapeutic agents and are also present as part of the pharmacological profile of psychotropic agents. However, the laboratory pharmacological characteristics of agents are a more reliable predictor of side effect profiles than they are of their therapeutic activities. Therefore, it would seem possible to be able to predict with much greater accuracy the clinically significant side effects that may be encountered from the preclinical data. This has been established in the case of trazodone and imipramine. The anticholinergic profile of imipramine was clearly determined in the laboratory and in man it produces a range of activity varying from mild peripheral anticholinergic activity to impairment of various functions involving vision, cardiovascular function and gastrointestinal activity. However, in the geriatric population, because of the vast amount of research implicating cholinergic mechanisms in memory functions and particularly in some aspects of cognitive deficit, it may be predicted that the anticholinergic activity of the tricyclics may present an especially troublesome pattern in a geriatric population that requires antidepressant therapy. These comparative effects between the two agents will be discussed and documented from control study data.

show abstract

“…Are there differences which could be explained by the weight history of the individual patient, or is the side effect of "carbohydrate craving' which is associated with amitriptyline treatment [Paykel et al 1973] the cause of weight gain? We were fortunate in being able to obtain data from a previously reported study [Goldberg et al, 1981] where there was a double blind comparison of amitriptyline, trazodone and pla cebo in which weight and height data were not previously analyzed. Both of these studies were combined for analy sis.…”

mentioning

confidence: 99%

Weight Changes in Antidepressants: A Comparison of Amitriptyline and Trazodone

Orzack¹,

Cole²,

Friedman³

et al. 1986

Neuropsychobiology

View full text Add to dashboard Cite

Weight data taken from a 6-week randomized double-blind study comparing amitriptyline, trazodone and placebo were analyzed to determine differential weight changes between the two drugs. In 272 depressed outpatients doses were increased over a period of 4 days to reach a maximum level of 200 mg amitriptyline or 400 mg trazodone. After grouping the subjects according to initial weights (ideal, overweight, 20% above, and underweight, 20% below) mean changes were determined for each treatment. The results indicate that amitriptyline, which differed from placebo and trazodone, produced significantly higher weight gains in the ideal and overweight groups. Trazodone on the other hand produced a slight weight loss in the overweight group. Due to a low number of patients in the underweight group, the results were not significant statistically. The antidepressant effects of both trazodone and amitriptyline were the same and no correlations between Hamilton scores and weight change were found.

show abstract

Treatment of Neurotic Depression with a New Antidepressant

Cited by 22 publications

References 0 publications

Trazodone: A 5-Year Review of Antidepressant Efficacy

Trazodone: A 5-Year Review of Antidepressant Efficacy

Comparative Side Effect Profiles of Trazodone and Imipramine: Special Reference to the Geriatric Population

Weight Changes in Antidepressants: A Comparison of Amitriptyline and Trazodone

Contact Info

Product

Resources

About